VSX2

Across TCGA pan-cancer cohorts, VSX2 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated VSX2 data layer compared with 5 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher VSX2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated VSX2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and DLBC show a favorable association.

STAD, LUAD, and LIHC are the cancer types where VSX2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Quartile	All	0.314	0.563	.001	83	view →
LUAD	DFS	Tertile	All	0.911	0.702	.001	63	view →
LIHC	OS	Tertile	All	0.383	0.542	.003	36	view →
ACC	DFS	Median	All	0.199	0.622	<.001	29	view →
DLBC	OS	Median	All	1.000	0.553	.003	29	view →
PAAD	DFS	Tertile	All	0.741	0.452	.010	26	view →
LUSC	DFS	Median	All	0.733	0.608	.001	24	view →
THCA	DFS	Median	II,III,IV	0.748	0.926	.001	21	view →
CESC	OS	Quartile	II,III,IV	0.905	0.663	.008	18	view →
KICH	OS	Quartile	II,III,IV	0.468	1.000	.026	17	view →
SCLC	OS	Tertile	All	0.788	0.474	.012	14	view →
KIRC	DFS	Tertile	All	0.499	0.650	.009	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

VSX2–STAD (OS)

Open the STAD breakdown →